Search Results - Alexandra Gruber‐Wackernagel

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Desired response to phototherapy vs photoaggravation in psoriasis: what makes the difference?

    Desired response to phototherapy vs photoaggravation in psoriasis: what makes the difference? by Peter Wolf, Wolfgang Weger, VijayKumar Patra, Alexandra Gruber‐Wackernagel, Scott N. Byrne

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis

    Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis by Tej Pratap Singh, Michael P. Schön, Katrin Wallbrecht, Alexandra Gruber‐Wackernagel, Xiao‐Jing Wang, Peter Wolf

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening

    Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening by Nina A. Schweintzger, Alexandra Gruber‐Wackernagel, Eleonora Reginato, Isabella Bambach, Franz Quehenberger, Scott N. Byrne, Peter Wolf

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides

    Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides by Pablo Vieyra-Garcia, Regina Fink‐Puches, Stefanie Porkert, Roland Lang, Sophie Pöchlauer, Gudrun Ratzinger, Adrian Tanew, Sylvia Selhofer, Paul-Gunther Sator, Angelika Hofer, Alexandra Gruber‐Wackernagel, Franz J. Legat, VijayKumar Patra, Franz Quehenberger, Lorenzo Cerroni, Rachael A. Clark, Peter Wolf

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*

    Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis* by Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, Wolfgang Weger, Claudia Kölli, Barbara Gruber, Paul-Gunther Sator, Karin Prillinger, Alexander Mlynek, Martina Schütz‐Bergmayr, Leo Richter, Gudrun Ratzinger, Clemens Painsi, Sylvia Selhofer, Nina Häring, Katharina Wippel‐Slupetzky, Hans Skvara, Hannes Trattner, Adrian Tanew, Martin Inzinger, Rafaella Tatarski, Christine Bangert, Christina Ellersdorfer, R. Lichem, Alexandra Gruber‐Wackernagel, Angelika Hofer, Franz J. Legat, Erich Schmiedberger, Robert Strohal, Bernhard Lange‐Asschenfeldt, Matthias Schmuth, Igor Vujic, Wolfram Hoetzenecker, Franz Trautinger, Werner Saxinger, Robert R. Müllegger, Franz Quehenberger, Peter Wolf

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: